- Home
- TSBX vs EDSA Comparison
TSBX vs EDSA Comparison
Compare TSBX & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSBX
- EDSA
- Stock Information
- Founded
- TSBX 2015
- EDSA 2015
- Country
- TSBX United States
- EDSA Canada
- Employees
- TSBX N/A
- EDSA N/A
- Industry
- TSBX
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- TSBX
- EDSA Health Care
- Exchange
- TSBX Nasdaq
- EDSA Nasdaq
- Market Cap
- TSBX 7.7M
- EDSA 13.8M
- IPO Year
- TSBX 2023
- EDSA N/A
- Fundamental
- Price
- TSBX $0.37
- EDSA $2.09
- Analyst Decision
- TSBX Buy
- EDSA Strong Buy
- Analyst Count
- TSBX 3
- EDSA 2
- Target Price
- TSBX $4.75
- EDSA $13.00
- AVG Volume (30 Days)
- TSBX 459.9K
- EDSA 13.3K
- Earning Date
- TSBX 08-13-2025
- EDSA 08-08-2025
- Dividend Yield
- TSBX N/A
- EDSA N/A
- EPS Growth
- TSBX N/A
- EDSA N/A
- EPS
- TSBX N/A
- EDSA N/A
- Revenue
- TSBX N/A
- EDSA N/A
- Revenue This Year
- TSBX N/A
- EDSA N/A
- Revenue Next Year
- TSBX N/A
- EDSA N/A
- P/E Ratio
- TSBX N/A
- EDSA N/A
- Revenue Growth
- TSBX N/A
- EDSA N/A
- 52 Week Low
- TSBX $0.29
- EDSA $1.55
- 52 Week High
- TSBX $2.69
- EDSA $5.59
- Technical
- Relative Strength Index (RSI)
- TSBX 54.35
- EDSA 55.09
- Support Level
- TSBX $0.33
- EDSA $2.03
- Resistance Level
- TSBX $0.37
- EDSA $2.11
- Average True Range (ATR)
- TSBX 0.02
- EDSA 0.10
- MACD
- TSBX 0.00
- EDSA 0.01
- Stochastic Oscillator
- TSBX 64.17
- EDSA 73.33
About TSBX Turnstone Biologics Corp.
Turnstone Biologics Corp is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The company is pioneering a differentiated approach to tumor-infiltrating lymphocytes, or TILs, a clinically validated technology for treating solid tumors. It is developing next-generation TIL therapies by selecting the most potent and tumor-reactive T cells, which are referred to as Selected TILs. TILs are a type of cell therapy that harnesses the patient's own immune cells to target their own tumors. TIL therapy involves the isolation of lymphocytes from the patient's tumor, expansion of the isolated cells outside the body, and then infusion of the cells back into the patient.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.